Please assess the completion status of the following clinical trial:

Trial Title: A 4-week Dose-Ranging, Dose-Interval, Efficacy, Safety and Tolerability Study of GSK961081 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient Subjects~* Subjects who give their signed and dated informed consent to participate~* 40 or more years of age, inclusive, at Visit 1~* Male or females~* Subjects with an established clinical history of COPD~* Current or previous cigarette smokers with a history of ≥ 10 pack-years of cigarette smoking~* Subjects with the following liver function test values:~* Subjects with a measured post-salbutamol FEV1/FVC ratio of \< 0.70 at Visit 1 (Screening).~* Subjects with a measured post-salbutamol FEV1 30-70% of predicted normal values~Exclusion Criteria:~* Women who are pregnant or lactating or are planning to become pregnant during the study.~* Current diagnosis of asthma~* Other significant respiratory disorders besides COPD, including alpha-1 deficiency~* Previous lung resection surgery~* Significant abnormalities in chest x-ray presentation~* Hospitalization for a COPD exacerbation within 12 weeks prior screening~* Use of oral corticosteroids or antibiotics for COPD or antibiotics for a lower respiratory tract infection within 6 weeks~* Any significant disease that would put subject at risk through study participation~* BMI greater than 35~* Pacemaker~* Significantly abnormal ECG, clinical lab finding (including Hepatitis B or C)~* Cancer~* Allergy or hypersensitivity to beta adrenergic receptor-agonist, sympathomimetic, anticholinergic/anti-muscarinic receptor antagonist, or inhaler excipients~* Diseases that would contra-indicate the use of anticholinergics~* Use of sysemic corticosteroids within 6 weeks of screening~* Use of long-acting beta-agonists within 48 hours of screening~* Use of tiotropium within 7 days of screening~* Use of theophyllines or anti-leukotrienes within 48 hours of screening~* Use of short-acting bronchodilators within 4 hours of screening~* Use of investigational medicines within 30 days of screening~* Use of high dose inhaled corticosteroids~* Use of long-term oxygen therapy, CPAP or NIPPV~* Participation in the acute phase of a pulmonary rehabilitation program within 4 weeks prior to Visit 1~* Regular (q.i.d or greater) use of short acting bronchodilators, including nebulized therapy~* Affiliation with Investigator Site~* Questionable Validity of Consent~* Previous use of GSK961081

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GSK961081 100 mcg QD (Type: EXPERIMENTAL): None
- GSK961081 100mcg BD (Type: EXPERIMENTAL): None
- GSK961081 200mcg QD (Type: EXPERIMENTAL): None
- GSK961081 400mcg QD (Type: EXPERIMENTAL): None
- GSK961081 400mcg BD (Type: EXPERIMENTAL): None
- GSK961081 800mcg QD (Type: EXPERIMENTAL): None
- Salmeterol 50mcg BD (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).